Carlos Rodríguez-Pascual1, Emilio Paredes-Galán2, Ana Isabel Ferrero-Martínez3, José Antonio Baz-Alonso4, Darío Durán-Muñoz5, Eva González-Babarro6, Marcelo Sanmartín7, Teresa Parajes3, Ivett Torres-Torres3, Miguel Piñón-Esteban5, Francisco Calvo-Iglesias2, Maria Teresa Olcoz-Chiva3, Fernando Rodríguez-Artalejo8. 1. Department of Geriatric Medicine, Hospital do Meixoeiro, Complejo Hospitalario Universitario de Vigo, Spain; University of Lincoln and Lincoln County Hospital, Lincoln, United Kingdom. Electronic address: CRodriguezpascual@lincoln.ac.uk. 2. Department of Cardiology, Hospital do Meixoeiro, Complejo Hospitalario Universitario de Vigo, Spain. 3. Department of Geriatric Medicine, Hospital do Meixoeiro, Complejo Hospitalario Universitario de Vigo, Spain. 4. Department of Interventional Cardiology, Hospital do Meixoeiro, Complejo Hospitalario Universitario de Vigo, Spain. 5. Department of Cardiovascular Surgery, Hospital do Meixoeiro, Complejo Hospitalario Universitario de Vigo, Spain. 6. Department of Cardiology, Complejo Hospitalario de Pontevedra, Spain. 7. Department of Cardiology, POVISA Hospital, Madrid, Spain. 8. Department of Preventive Medicine and Public Health, Universidad Autónoma de Madrid/IdiPaz, CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Abstract
BACKGROUND: The role of frailty as a prognostic factor in non-selected patients with symptomatic severe aortic stenosis (SAS) is still uncertain. This study aims to examine the association between the frailty syndrome and mortality among very old patients with symptomatic SAS, and to assess whether the association varies with the type of SAS treatment. METHODS AND RESULTS: Prospective study of 606 patients aged ≥75years with symptomatic SAS, recruited from February 2010 to January 2015, who were followed up through June 2015. At baseline, frailty was defined as having at least three of the following five criteria: muscle weakness, slow gait speed, low physical activity, exhaustion, and unintentional weight loss. Statistical analyses were performed with multivariate Cox regression. At baseline, 49.3% patients were frail. During a mean follow-up of 98weeks, 35.3% of patients died. The hazard ratio (95% confidence interval) of mortality among frail versus non-frail patients was 1.83 (1.33-2.51). The corresponding results were 1.58 (1.09-2.28) among patients under medical treatment, 3.06 (1.25-7.50) in those with transcatheter aortic valve replacement, and 1.97 (0.83-4.67) in those with surgical aortic valve replacement, p for interaction=0.21. When the frailty criteria were considered separately, mortality was also higher among patients with slow gait speed [1.52 (1.05-2.19)] or low physical activity [1.35 (1.00-1.85)]. CONCLUSIONS: Frailty is associated with increased mortality among patients with symptomatic SAS, and this association does not vary with the type of SAS treatment. Future studies evaluating the benefits of different treatments in SAS patients should account for baseline frailty.
BACKGROUND: The role of frailty as a prognostic factor in non-selected patients with symptomatic severe aortic stenosis (SAS) is still uncertain. This study aims to examine the association between the frailty syndrome and mortality among very old patients with symptomatic SAS, and to assess whether the association varies with the type of SAS treatment. METHODS AND RESULTS: Prospective study of 606 patients aged ≥75years with symptomatic SAS, recruited from February 2010 to January 2015, who were followed up through June 2015. At baseline, frailty was defined as having at least three of the following five criteria: muscle weakness, slow gait speed, low physical activity, exhaustion, and unintentional weight loss. Statistical analyses were performed with multivariate Cox regression. At baseline, 49.3% patients were frail. During a mean follow-up of 98weeks, 35.3% of patients died. The hazard ratio (95% confidence interval) of mortality among frail versus non-frail patients was 1.83 (1.33-2.51). The corresponding results were 1.58 (1.09-2.28) among patients under medical treatment, 3.06 (1.25-7.50) in those with transcatheter aortic valve replacement, and 1.97 (0.83-4.67) in those with surgical aortic valve replacement, p for interaction=0.21. When the frailty criteria were considered separately, mortality was also higher among patients with slow gait speed [1.52 (1.05-2.19)] or low physical activity [1.35 (1.00-1.85)]. CONCLUSIONS: Frailty is associated with increased mortality among patients with symptomatic SAS, and this association does not vary with the type of SAS treatment. Future studies evaluating the benefits of different treatments in SAS patients should account for baseline frailty.
Authors: Pablo Solla-Suárez; Pablo Avanzas; Isaac Pascual; Manuel Bermúdez-Menéndez De La Granda; Marcel Almendarez; Jose M Arche-Coto; Daniel Hernández-Vaquero; Rebeca Lorca; Eva López-Álvarez; Rut Álvarez-Velasco; Carmen Moreno-Planillo; César Morís de la Tassa; José Gutiérrez-Rodríguez Journal: J Clin Med Date: 2021-05-27 Impact factor: 4.241
Authors: M S van Mourik; J F Velu; V R Lanting; J Limpens; B J Bouma; J J Piek; J Baan; J P S Henriques; M M Vis Journal: Neth Heart J Date: 2020-05 Impact factor: 2.380